FinTrade Sherpa, Inc. (FTSP)
OTCMKTS · Delayed Price · Currency is USD
0.0300
0.00 (0.00%)
Aug 1, 2025, 4:00 PM EDT

Verve Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Selling, General & Admin
0.210.070.050.130.180.21
Upgrade
Operating Expenses
0.210.070.050.130.210.23
Upgrade
Operating Income
-0.21-0.07-0.05-0.13-0.21-0.23
Upgrade
Interest Expense
----0-0.07-0.08
Upgrade
Other Non Operating Income (Expenses)
-0.01-0.01-0.01-0.03-0.1-0.12
Upgrade
EBT Excluding Unusual Items
-0.22-0.08-0.06-0.16-0.38-0.44
Upgrade
Asset Writedown
------0.05
Upgrade
Pretax Income
-0.22-0.08-0.062.03-2.57-0.49
Upgrade
Net Income
-0.22-0.08-0.062.03-2.57-0.49
Upgrade
Net Income to Common
-0.22-0.08-0.062.03-2.57-0.49
Upgrade
Shares Outstanding (Basic)
122121121885151
Upgrade
Shares Outstanding (Diluted)
122121121885151
Upgrade
Shares Change (YoY)
1.12%-37.73%73.43%0.05%-
Upgrade
EPS (Basic)
-0.00-0.00-0.000.02-0.05-0.01
Upgrade
EPS (Diluted)
-0.00-0.00-0.000.02-0.05-0.01
Upgrade
EBIT
-0.21-0.07-0.05-0.13-0.21-0.23
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.